We’re moving to eviCore criteria for certain multi-gene panels
We've heard you and will no longer require attestation for advanced care planning and clinical trial enrollment prior to approval for certain multi-gene panels starting April 19, 2021. Instead, we’ll adopt eviCore criteria for these tests.
You can preview the April 19 policy changes on eviCore's website.
Specifically, we adopted the following criteria:
- Liquid Biopsy Testing (MOL.TS.194.A): pg. 625
- Somatic Mutation Testing - Hematological Malignancies (MOL.TS.313.A): pg 936
- Somatic Mutation Testing- Solid Tumors (MOL.TS.230.A): pg 947